May 13, 2020 6:30am EDT Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%
May 12, 2020 12:00pm EDT Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19
May 06, 2020 8:30am EDT Veru to Report Fiscal 2020 Second-Quarter Financial Results, Host Conference Call on May 13th
May 05, 2020 8:30am EDT Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program
Feb 26, 2020 8:30am EST Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug
Feb 12, 2020 6:30am EST Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%
Feb 05, 2020 8:30am EST Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th
Jan 21, 2020 8:30am EST Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020
Jan 13, 2020 8:00am EST Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy
Dec 12, 2019 6:30am EST Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%
